Journal Article (Review Article)

DKFZ-2021-00182

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Parvovirus-Based Combinatorial Immunotherapy: A Reinforced Therapeutic Strategy against Poor-Prognosis Solid Cancers.

Angelova, A. L. (First author)DKFZ* ; Ferreira, T.DKFZ* ; Bretscher, C.DKFZ* ; Rommelaere, J.DKFZ* ; Marchini, A. (Last author)DKFZ*

2021
MDPI Basel

This record in other databases:  

Please use a persistent id in citations: doi:10.3390/cancers13020342

Abstract: Resistance to anticancer treatments poses continuing challenges to oncology researchers and clinicians. The underlying mechanisms are complex and multifactorial. However, the immunologically 'cold' tumor microenvironment (TME) has recently emerged as one of the critical players in cancer progression and therapeutic resistance. Therefore, TME modulation through induction of an immunological switch towards inflammation ('warming up') is among the leading approaches in modern oncology. Oncolytic viruses (OVs) are seen today not merely as tumor cell-killing (oncolytic) agents, but also as cancer therapeutics with multimodal antitumor action. Due to their intrinsic or engineered capacity for overcoming immune escape mechanisms, warming up the TME and promoting antitumor immune responses, OVs hold the potential for creating a proinflammatory background, which may in turn facilitate the action of other (immunomodulating) drugs. The latter provides the basis for the development of OV-based immunostimulatory anticancer combinations. This review deals with the smallest among all OVs, the H-1 parvovirus (H-1PV), and focuses on H-1PV-based combinatorial approaches, whose efficiency has been proven in preclinical and/or clinical settings. Special focus is given to cancer types with the most devastating impact on life expectancy that urgently call for novel therapies.

Keyword(s): colorectal cancer ; combination therapy ; glioblastoma ; immunotherapy ; melanoma ; oncolytic ; pancreatic cancer ; parvovirus ; tumor microenvironment

Note: #EA:F230#LA:F011#

---

Contributing Institute(s):

1. KKE Virotherapie (F230)
2. F011 LOVIT (F011)

Research Program(s):

1. 316 - Infektionen, Entzündung und Krebs (POF4-316) (POF4-316)

Appears in the scientific report 2021

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---